Ranibizumab plus PRP induces neovascularization regression in diabetic retinopathy
Administering intravitreal injections of ranibizumab (RBZ) in addition to panretinal photocoagulation (PRP) appears to be more effective than PRP monotherapy in terms of neovascularization (NV) regression in patients with high-risk proliferative diabetic retinopathy (HR-PDR), according to a study.
The 12-week, open-label, phase II/III study included 87 adult patients with type 1/2 diabetes and HR-PDR (mean age 55.2 years; 37 percent female) who were randomized to receive PRP in combination with RBZ (n=41) or as monotherapy (n=46). Patients in the RBZ+PRP group received three monthly RBZ injections along with standard PRP, while those in the PRP monotherapy group received PRP between day 1 and month 2.
Of the patients, 88.5 percent completed the study. Significantly more patients in the RBZ+PRP group vs PRP monotherapy group presented regression of NV at month 12 (92.7 percent vs 70.5 percent; p=0.009).
Likewise, the proportion of patients showing any decrease in the area of NV on the disc (NVD) and elsewhere (NVE) was higher in the RBZ+PRP group (93.3 percent and 91.4 percent, respectively vs 68.8 percent and 73.7 percent, respectively, in the PRP monotherapy group), although the difference was significant only for NVE (p=0.048).
Complete NV total regression was seen in 43.9 percent in the RBZ+PRP group vs 25.0 percent in the PRP monotherapy group (p=0.066).
With respect to other outcomes, best-corrected visual acuity changes from baseline to month 12 were similar between the two treatment groups (75.2 letters with RBZ+PRP vs 69.2 letters with PRP monotherapy; p=0.104). The mean number of PRP treatments during the study period was significantly lower in the RBZ+PRP group than in the PRP monotherapy group (3.5 vs 4.6; p=0.001). No deaths or unexpected AEs were reported.